Deferoxamine retinopathy: Spectral domain-optical coherence tomography findings

BMC Ophthalmology

Volumn 14, Issue 1, 2014, Pages

  Wu, Cheng Hsiu ^a   Yang, Chao Ping ^a,b   Lai, Chi Chun ^a,b   Wu, Wei Chi ^a,b   Chen, Yi Hsing ^a,b  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

Author keywords

Deferoxamine; Retinopathy; Spectral domain optical coherence tomography

Indexed keywords

DEFEROXAMINE; SIDEROPHORE;

ADULT; CASE REPORT; CHEMICALLY INDUCED; DOSE RESPONSE; DRUG EFFECTS; EYE FUNDUS; FLUORESCENCE ANGIOGRAPHY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; OPTICAL COHERENCE TOMOGRAPHY; PATHOLOGY; PIGMENT EPITHELIUM; PROCEDURES; RETINAL DISEASES; THALASSEMIA; VISUAL ACUITY;

ADULT; DEFEROXAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FLUORESCEIN ANGIOGRAPHY; FUNDUS OCULI; HUMANS; INJECTIONS, INTRAVENOUS; MALE; RETINAL DISEASES; RETINAL PIGMENT EPITHELIUM; SIDEROPHORES; THALASSEMIA; TOMOGRAPHY, OPTICAL COHERENCE; VISUAL ACUITY;

EID: 84903409630     PISSN: None     EISSN: 14712415     Source Type: Journal    
DOI: 10.1186/1471-2415-14-88     Document Type: Article

References (13)

1. Transfusional iron overload and chelation therapy with deferoxamine and deferiprone (L1). Kontoghiorghes GJ, Pattichi K, Hadjigavriel M, Kolnagou A, Transfus Sci 2000 23 3 211 223
2. Deferoxamine (Desferal)-induced toxic retinal pigmentary degeneration and presumed optic neuropathy. Lakhanpal V, Schocket SS, Jiji R, Ophthalmol 1984 91 5 443 451 (Pubitemid 14149071)
3. Deferoxamine-related ocular toxicity: incidence and outcome in a pediatric population. Baath JS, Lam WC, Kirby M, Chun A, Retina 2008 28 6 894 899
4. Deferoxamine Retinopathy Study G: The expanded clinical spectrum of deferoxamine retinopathy. Haimovici R, D'Amico DJ, Gragoudas ES, Sokol S, Ophthalmology 2002 109 1 164 171 (Pubitemid 34027442)
5. Desferrioxamine related maculopathy: a case report. Arora A, Wren S, Gregory Evans K, Am J Hematol 2004 76 4 386 388 (Pubitemid 38988626)
6. Desferrioxamine-related ocular toxicity: a case report. Simon S, Athanasiov PA, Jain R, Raymond G, Gilhotra JS, Indian J Ophthalmol 2012 60 4 315 317
7. Abnormal fundus autofluorescence results of patients in long-term treatment with deferoxamine. Viola F, Barteselli G, Dell'arti L, Vezzola D, Villani E, Mapelli C, Zanaboni L, Cappellini MD, Ratiglia R, Ophthalmol 2012 119 8 1693 1700
8. Multimodal Imaging in Deferoxamine Retinopathy. Viola F, Barteselli G, Dell'arti L, Vezzola D, Mapelli C, Villani E, Ratiglia R, Retina 2013 0 1 11
9. Ocular toxicity of desferrioxamine: light microscopic histochemical and ultrastructural findings. Rahi AH, Hungerford JL, Ahmed AI, Br J Ophthalmol 1986 70 5 373 381 (Pubitemid 16114190)
10. Multiple transfused thalassemia major: ocular manifestations in a hospital-based population. Taneja R, Malik P, Sharma M, Agarwal MC, Indian J Ophthalmol 2010 58 2 125 130
11. Cerebral and ocular toxicity induced by desferrioxamine. Blake DR, Winyard P, Lunec J, Williams A, Good PA, Crewes SJ, Gutteridge JM, Rowley D, Halliwell B, Cornish A, Hider RC, Q J Med 1985 56 219 345 355 (Pubitemid 15048917)
12. Depletion of trace elements and acute ocular toxicity induced by desferrioxamine in patients with thalassaemia. De Virgiliis S, Congia M, Turco MP, Frau F, Dessi C, Argiolu F, Sorcinelli R, Sitzia A, Cao A, Arch Dis Child 1988 63 3 250 255 (Pubitemid 18094662)
13. Ocular toxicity of high-dose intravenous desferrioxamine. Davies SC, Marcus RE, Hungerford JL, Miller MH, Arden GB, Huehns ER, Lancet 1983 2 8343 181 184 (Pubitemid 13072937)